AFMD - AbCheck teams up to use microfluidics tech to discover antibodies for neurological disorder

• Affimed's ( NASDAQ: AFMD ) unit AbCheck said it is collaborating with a biotech company which develops antibodies targeting peripheral neural response, funded by an European venture capital firm.
• Under the agreement, AbCheck will use its technology suite consisting of antibody discovery technologies to deliver antibodies against an undisclosed neurology target with a challenging target product profile, the company added.
• AbCheck noted that its drug discovery platform based on its microfluidics technology is aimed to overcome target-specific challenges and improve success rates for drug discovery campaigns.
• "Our proprietary microfluidics platform, which enables functional screening for millions of single cells per day, has been specifically designed to deliver antibodies against targets with particularly complex Target Product Profiles," said AbCheck Managing Director Volker Lang.
• AFMD +1.96% to $1.04 premarket Feb. 21

For further details see: